© H. Zell · CC BY-SA 3.0 · Commons
Echinacea purpurea
CautionPurpur-Sonnenhut · (Echinacea purpurea)
Daisy family (Asteraceae)
Description
A cone-shaped, coppery-orange centre ringed by drooping, vivid purple ray florets makes this coneflower easy to spot in prairies and gardens alike. The flowering aerial parts are gathered between July and September and are notably rich in alkylamides, caffeic acid derivatives such as cichoric acid, plus polysaccharides and inulin. Tinctures and pressed juice from the herb are classed by the EMA as well-established for supporting the body's own defences at the first signs of a cold, a use also described in the Commission E monograph. The root is used traditionally as well, and external preparations are applied to minor skin irritation. Because it stimulates immune activity, echinacea is contraindicated in autoimmune disease, immunodeficiency, or immunosuppressive therapy, and people with Asteraceae allergies should be cautious of cross-reactions.
CONTRAINDICATED for children
Per EMA not recommended for children under 12 — insufficient safety data. Additionally, increased risk of allergic reactions in children with atopic conditions. For children under 12 with signs of infection always seek medical evaluation; no Echinacea self-medication.
Critical drug interactions with:
Immunsuppressiva (Ciclosporin, Tacrolimus, Azathioprin, Methotrexat, Mycophenolat, Kortikosteroide in immunsuppressiver Dosis)
Expressed juice from fresh flowering herb (EMA well-established use) for short-term prevention and treatment of upper respiratory tract colds.
Preparation & dosage
EXPRESSED JUICE (EMA well-established use): Expressed juice from fresh flowering herb (Echinaceae purpureae herba recens), DER 1.5–2.5:1, no solvent. Single dose 1.5–4.5 ml, daily dose 6–9 ml, oral. Dilute in water if desired. Start at first signs of cold (scratchy throat, mild chills). Do not use for more than 10 days (≈1.5 weeks). If symptoms persist beyond 10 days or fever exceeds 39 °C: seek medical advice. Do not combine with immunosuppressants. Do not apply to atopic eczema, wounds or inflamed mucous membranes.
- Liquid amount
- 1.5–4.5 ml
- Doses per day
- 3×
- Max duration
- 1.5 weeks
⚠ Age restriction: ≥ 12 years — Per EMA, adults and adolescents 12 years and older only — insufficient data for children under 12.
Root tincture or dry extract for traditional treatment of upper respiratory colds — EMA traditional use.
Preparation & dosage
ROOT TINCTURE / DRY EXTRACT (EMA traditional use): Root tincture (DER 1:5 in ethanol 55 % V/V): 1–2 ml 3× daily. Alternatively dry extract (DER 5.5–7.5:1, ethanol 45 % V/V): 40 mg every 2 hours, daily dose 360 mg. For supportive treatment of colds and upper respiratory infections. Do not exceed 10 days. Seek medical advice if worsening or fever above 39 °C. Do not use in autoimmune diseases, immunosuppression or progressive systemic disorders.
- Liquid amount
- 1–2 ml
- Doses per day
- 3×
- Max duration
- 1.5 weeks
⚠ Age restriction: ≥ 12 years — Adults and adolescents 12+ only — insufficient data for children under 12.
Infusion from dried herb for traditional support during colds and mild upper respiratory infections.
Preparation & dosage
INFUSION (traditional use): 1–2 g dried Echinacea herb (or herb/root blend) in 200 ml boiling water, covered, steep 10 min, strain. 3× daily fresh. Daily dose ~3–6 g herb. Start at first signs of cold. Do not use longer than 10 days. Tea is less concentrated than expressed juice or extract — suitable as adjunct or for mild symptoms. Do not use in Asteraceae allergy.
- Dry amount
- 1–2 g
- Doses per day
- 3×
- Max duration
- 1.5 weeks
⚠ Age restriction: ≥ 12 years — Not recommended for children under 12 — insufficient data.
Expressed juice for prophylactic immune support during cold season — Kommission E positive, max. 8 weeks continuous therapy.
Preparation & dosage
ECHINACEA JUICE FOR IMMUNE PROPHYLAXIS (Kommission E): Daily dose 6–9 ml expressed juice from fresh flowering herb, oral. Prophylactic use to strengthen natural defences; e.g. during cold season or recurrent infections. Do not use continuously for more than 8 weeks — then at least 2–4 weeks break. Long-term use without pause is not recommended due to possible tolerance and insufficient safety data. Do not use in autoimmune diseases, MS, TB, leukaemia or HIV/AIDS.
- Liquid amount
- 6–9 ml
- Doses per day
- 1×
- Max duration
- 8 weeks
⚠ Age restriction: ≥ 12 years — Children under 12: not recommended.
External salve or cream with expressed juice for superficial wounds, abrasions and mild skin inflammation — EMA traditional use.
Preparation & dosage
SALVE / CREAM (external, traditional use): Preparations with 10–20 g expressed juice / 100 g ointment base. Apply thinly to affected area 2–3× daily. Indications: small, superficial abrasions, pressure marks, early insect stings (anti-inflammatory). Do not apply to deep, large, or infected wounds. Do not apply to breast of breastfeeding women. Do not use longer than 7 days without medical advice. If signs of infection appear (redness, warmth, pus, spread) seek medical treatment immediately.
- Doses per day
- 3×
- Max duration
- 1 weeks
Root dry extract as adjuvant for mild acne — traditional use per EMA.
Preparation & dosage
ROOT DRY EXTRACT FOR MILD ACNE (EMA traditional use): Dry extract from root (DER 4:1, water solvent): 50–100 mg single dose, 150–300 mg daily. Oral, taken with meals. Adjuvant for mild acne (spots, blackheads, mild inflammatory lesions). Not a substitute for dermatological therapy in moderate-to-severe acne. Seek medical advice if symptoms persist beyond 2 weeks or worsen.
- Dry amount
- 0.05–0.1 g
- Doses per day
- 3×
- Max duration
- 2 weeks
⚠ Age restriction: ≥ 12 years — Not for children under 12 years.
Folk root decoction for fever and infections — historical use by Native Americans, later adopted by Eclectic physicians and European folk medicine.
Preparation & dosage
ROOT DECOCTION (folk use): 1–2 g dried, coarsely chopped Echinacea root in 250 ml cold water, bring to boil, simmer 10–15 min (decoction), strain, cool. 3× daily for fever, influenza-like illness and as traditional blood-purifier of indigenous peoples (Lakota, Cheyenne). Historical background: Echinacea was among the most-used remedies of Plains Indians — bite wounds, snakebite, sore throat, toothache. In Europe widely used folk medicinally for immune support. For high fever (above 39.5 °C) or fever persisting more than 3 days: seek medical advice.
- Dry amount
- 1–2 g
- Doses per day
- 3×
- Max duration
- 1 weeks
IMPORTANT — CONTRAINDICATIONS APPLY: Echinacea stimulates the immune system and is CONTRAINDICATED in autoimmune diseases (lupus erythematosus, rheumatoid arthritis, multiple sclerosis), immunodeficiencies (HIV/AIDS), progressive systemic disorders (tuberculosis, leukaemias, collagenoses), and under immunosuppressive therapy (post-transplantation, cytostatics, high-dose corticosteroids). Duration of use: no longer than 10 days for acute infections; for prophylactic use no longer than 8 consecutive weeks without at least a 2-week break. Allergy risk: cross-reactions with other Asteraceae (ragweed, chamomile, calendula) possible — do NOT use Echinacea if allergic to Asteraceae. Atopic individuals (asthma, hay fever, eczema) have elevated allergy risk; first use cautiously. Discontinue immediately and seek medical help if symptoms worsen or allergic reactions occur (rash, dyspnoea, swallowing difficulty). NOT a substitute for vaccination.
⏱ Max continuous use: 1.5 weeks
Per EMA not recommended in pregnancy due to insufficient data. Two prospective observational studies found no increased miscarriage risk with short-term first-trimester use, but data remain insufficient for a positive recommendation. Avoid therapeutic use — culinary use (e.g. occasional herbal tea in household amounts) is not considered a relevant risk.
Per EMA not recommended during lactation due to lack of data. Transfer into breast milk not studied. External application to the breast of breastfeeding women is not recommended (infant may ingest residues).
Per EMA not recommended for children under 12 — insufficient safety data. Additionally, increased risk of allergic reactions in children with atopic conditions. For children under 12 with signs of infection always seek medical evaluation; no Echinacea self-medication.
Drug interactions
Immunsuppressiva (Ciclosporin, Tacrolimus, Azathioprin, Methotrexat, Mycophenolat, Kortikosteroide in immunsuppressiver Dosis)
Echinacea non-specifically stimulates cellular and humoral immune responses (macrophage activation, NK-cell stimulation, cytokine release IL-1, IL-6, TNF-α). Theoretical antagonism with immunosuppressants — risk of undermining immunosuppressive therapy, e.g. post-transplant. Combination contraindicated.
CYP3A4-Substrate (z. B. Midazolam, Ciclosporin, Saquinavir, Alprazolam, Statine)
In vitro and clinical studies (e.g. Gorski et al. 2004) show Echinacea extracts can both inhibit and induce CYP3A4 depending on preparation and route. Clinical relevance with short-term use at normal doses is likely minor, but caution is warranted with long-term use and narrow therapeutic window drugs (ciclosporin, saquinavir).
Hepatotoxische Arzneimittel (Amiodaron, Methotrexat, Ketoconazol, Anabolika)
Per EMA, Echinacea root preparations should not be combined with known hepatotoxic drugs due to potential hepatotoxicity (historically pyrrolizidine alkaloid impurities; negligible in quality preparations). Relevance for herb preparations is considerably lower.
Contraindications
- Hypersensitivity to Echinacea species or other Asteraceae/Compositae — including ragweed, chrysanthemum, calendula, yarrow, chamomile.
- Autoimmune diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis and other demyelinating conditions.
- Immunodeficiency: HIV infection/AIDS and primary or secondary immune defects.
- Progressive systemic disorders: tuberculosis, leukaemias, lymphomas, collagenoses.
- Immunosuppressive therapy: post-organ transplantation or under cytostatic or high-dose corticosteroid treatment.
- Children under 12 years — insufficient safety data.
- Pregnancy and lactation (therapeutic doses) — not recommended due to lack of data.
Harvested part: flowering herb
- Time of day:
- On a dry, sunny morning (9–12), after dew has evaporated. Harvest flowering stems with at least one open ray floret — constituent content (alkylamides, cichoric acid, polysaccharides) is highest at full bloom. Avoid stems not yet open or already past bloom.
- Drying:
- Cut stems approx. 30–40 cm (leave ~1/3 of plant — it is perennial, do not overharvest!). Coarsely chop leaves and stems or bundle into bundles. Dry on drying racks single-layered at max. 35–40 °C in shade with good air circulation. For expressed juice: press immediately from fresh material and process or freeze — the polysaccharide-rich fraction is only fully present in fresh herb. Discard if mould spots or musty odour appear. Store dried herb airtight and protected from light; use within 1 year.
- Storage:
- 12 months — Airtight in dark glass jars or tins, dry and cool (below 25 °C). Use within 1 year — constituent loss accelerates thereafter (especially cichoric acid and alkylamides oxidise). Discard if browning or characteristic scent fades.
- Time of day:
- Dry, cool days in late autumn (October–November) after aerial parts have died back. Harvest roots from plants at least 3–4 years old — younger roots contain fewer active constituents. Do not harvest in spring (plants need reserves for new growth).
- Drying:
- Carefully dig roots (garden fork, not spade — wounds promote rotting). Shake off soil, clean with brush, briefly rinse, allow to drain well. Halve lengthways or slice 3–5 mm thick. Dry at 40–50 °C in dehydrator or oven with door slightly ajar for 12–20 hours until slices are brittle-hard. Store on wire racks — no solid surfaces (mould risk). Properly dried root snaps cleanly and has a characteristic slightly sharp-aromatic scent. If soft spots remain, repeat drying process.
- Storage:
- 24 months — Airtight in dark glass jars or paper bags (not plastic — condensation risk), cool and dry. Root drug keeps up to 2 years when dry and cool. Check for mould and pests. Ground root should be used quickly (within 6 months) — surface area accelerates oxidation.
- Alkylamide (Isobutylamide der Polyenfettsäuren, v. a. Dodeca-2E,4E,8Z,10E/Z-tetraensäure-isobutylamid)OtherContent: 0.01-0.15 %Aerial parts
Lead compounds of herb and root fractions; responsible for the characteristic tingling sensation when chewing fresh plant material. Immunomodulatory via CB2 cannabinoid receptors and inhibition of 5-lipoxygenase and COX-2; anti-inflammatory and antifungal properties in vitro. Primarily in herb and root; barely in seeds. Lipophilic — lower in expressed juice than in ethanolic extracts.
- Kaffeesäurederivate: Cichoriensäure (Dicaffeoyltartrat) und EchinacosidePhenolic acidContent: 0.6-2.1 %Aerial parts
Cichoric acid is the dominant phenolic acid in the herb (0.6–2.1 % DW) associated with antioxidant, antiviral (hyaluronidase inhibition) and immunomodulatory effects in vitro. Echinacoside (phenylpropanoid glycoside) is higher in E. pallida/E. angustifolia and serves for species differentiation; only trace amounts in E. purpurea. Both are detectable in expressed juice and aqueous-ethanolic extracts.
- Polysaccharide (Arabinogalaktan, Heteroglukan, Fucogalakturonan)PolysaccharideContent: 3-6 %Aerial parts
High-molecular-weight polysaccharides from the aqueous fraction of expressed juice; activate macrophages and dendritic cells, stimulate production of IL-1, TNF-α and interferon. Main contributors to immunostimulatory effect of expressed juice in vitro and in animal models. Poorly absorbed orally due to high molecular weight — in vivo relevance after oral intake unclear. Barely present in tinctures due to ethanol precipitation.
- Flavonoide (Rutin, Quercetin-3-O-glucosid, Kaempferol-Derivate, Luteolin-7-O-glucosid)FlavonoidContent: 0.3-0.8 %Flower
Flavonoids in flowers and leaves; antioxidant, anti-inflammatory and capillary-stabilising. Quantitatively less important than in other medicinal plants (e.g. hawthorn, elderberry), but contribute to overall extract activity. Rutin and luteolin derivatives inhibit 5-lipoxygenase and histamine release in vitro.
- Glykoproteine und Arabinogalaktan-Proteine (AGP)OtherContent: 0.1-0.3 %Aerial parts
Water-soluble glycoproteins and arabinogalactan proteins (AGP) activate macrophages and T-lymphocytes in vitro. Discussed together with polysaccharides as carriers of non-specific immune stimulation. Thermolabile — partially denatured by boiling (tea preparation). Present in standardised expressed juices and liquid extracts.
- Ätherisches Öl (Borneol, Bornylacetat, Germacren D, Caryophyllen)Essential oilContent: 0.1-0.35 %Aerial parts
Essential oil in herb and flowers with sesquiterpene main components (germacrene D, β-caryophyllene). Antimicrobial and anti-inflammatory in vitro; pharmacologically relevant via inhalation or topical route; negligible after oral ingestion at therapeutic quantities. Proportion in expressed juice is low due to the aqueous solvent system.
- Inulin und FructooligosaccharidePolysaccharideContent: 5.9-6.5 %Root
Inulin as the main storage carbohydrate of the root (up to ~6.5 % in autumn when reserves are stored). Prebiotic effect in the gut; contributes to mild immunomodulatory activity in gut-associated lymphoid tissue (GALT). Partly explains the different activity profiles of root versus herb preparations.
- Pyrrolizidinalkaloid-Spuren (Tussilagin, Isotussilagin — unter Grenzwert)AlkaloidContent: < 0.001 %Aerial parts
Traces of amidine-type PAs (tussilagin, isotussilagin) in some Echinacea species and batches; non-hepatotoxic unlike classical 1,2-unsaturated PAs (Senecio, Symphytum). Well-manufactured, quality-controlled preparations remain well below the 1 µg/day threshold (EMA recommendation for 1,2-unsaturated PAs). Relevant only in poor-quality preparations or species misidentification.
- [1]MonographEMA/HMPC/48704/2014 Corr. — European Union herbal monograph on Echinacea purpurea (L.) Moench., herba recens (Final, 24 November 2015)(accessed: 2026-05-21)
- [2]MonographEMA/HMPC/424583/2016 — European Union herbal monograph on Echinacea purpurea (L.) Moench., radix (Final, 30 May 2017)(accessed: 2026-05-21)
- [3]MonographKommission E — Echinaceae purpureae herba (Purpursonnenhutkraut), positive Monographie, BAnz Nr. 43 vom 2. März 1989(accessed: 2026-05-21)
- [4]MonographESCOP Monographs — Echinaceae purpureae herba (Purple Coneflower Herb), 2nd edition with supplement(accessed: 2026-05-21)
- [5]MonographWHO Monographs on Selected Medicinal Plants — Volume 1: Herba Echinaceae Purpureae(accessed: 2026-05-21)
- [8]MonographPlants For A Future (PFAF) — Echinacea purpurea database entry(accessed: 2026-05-21)
- [6]BookWichtl, M. (Hrsg.) — Teedrogen und Phytopharmaka, 5. Auflage, Wissenschaftliche Verlagsgesellschaft Stuttgart, 2009: Echinaceae purpureae herba, S. 194–199(accessed: 2026-05-21)
- [7]BookMadaus, Gerhard — Lehrbuch der biologischen Heilmittel, Band I: Echinacea, 1938 (Public Domain)(accessed: 2026-05-21)